Sooner or later, a courteous email will land in your inbox asking whether you have “considered your options” for the practice. That is private equity introducing itself, and these days it introduces itself often. More than 30% of U.S. dentists were affiliated with a DSO by 2023, up from just 16% in 2017, and by some industry estimates DSOs sat on the buy side of more than half of all practice acquisitions in 2024. The consolidation is real, it is accelerating, and it runs on a playbook worth understanding before one shows up at your door.

The legal workaround: the “friendly PC”

Start with the problem private equity had to solve. Most states enforce a corporate practice of dentistry doctrine: non-dentists may not own a dental practice. So how does a fund that is not a dentist buy in? Through a two entity structure now standard across the industry. A licensed dentist owns the clinical practice, the “friendly PC,” or captive professional corporation, while the PE-backed management services organization (the DSO) owns the non-clinical assets and signs a long term management services agreement with it. Under that contract the MSO runs everything that is not clinical care: billing, marketing, HR, supplies, real estate, IT, and collects a management fee that captures most of the practice’s profit. The one legal tripwire: the MSO must not exert “undue control” over clinical judgment, or the structure risks collapsing under state law.

The roll-up: platform plus add-ons

No fund buys a single practice and stops. The strategy is a roll-up. A firm first acquires a substantial group, the platform, then bolts on smaller practices, one after another, as add-ons. Dental care has proved especially fertile ground: in 2024 it saw more deal activity than any health care sector the Private Equity Stakeholder Project tracks, with 137 add-on acquisitions in a single year.

The real engine: multiple arbitrage

Here is the financial trick that makes the whole thing worth doing, and it has remarkably little to do with dentistry. Practices are valued at a multiple of EBITDA — essentially profit. According to dental M&A bankers, a single location practice or add-on typically trades at roughly 5 to 8 times EBITDA, while multi-location platforms fetch 9 to 12 times or more. Now watch what that gap does. A DSO buys a dozen small practices at, say, six times earnings, staples them together, and the combined entity is valued at ten or eleven times the same earnings when it sells to the next buyer. Value is manufactured by aggregation, largely independent of any clinical improvement. Institutions pay a premium for scale and diversified risk, and the spread between the small practice multiple and the platform multiple is where much of the return is made.

What the selling dentist actually gets

For the dentist on the other side of the table, the offer is rarely a simple check. A typical DSO deal is a composite: 60 to 80% of the price paid in cash at closing, 15 to 30% taken as rollover equity in the larger DSO, and the remainder held back in earnouts tied to the practice’s retained profit over the next one to three years. The rollover is the interesting part. When the DSO is later sold to the next private equity buyer, a secondary sale or recapitalization, pays out again. The industry calls it the “second bite of the apple,” and for some sellers the second bite has beaten the first. The risk is equally real: the equity is illiquid, the timeline is out of your hands, and if the platform stumbles, the second bite can shrink or vanish.

The deal, step by step

Why now

None of this is happening in a vacuum. A generation of practice owners is nearing retirement; new graduates carry six-figure debt that makes buying a first practice feel reckless, which makes the salaried associate role a DSO offers look rational; and a decade of cheap-ish capital went hunting for health care roll-ups. The result is a U.S. DSO market that, by one industry estimate, reached about $44.7 billion in 2025 and is projected to keep compounding at a double-digit clip. Big name funds such as KKR, Blackstone, and many others are all in.

The criticism that rides along

Consolidation at this speed has critics, and their worry is specific: when outside investors layer growth targets and return clocks onto clinical care, the incentive to over treat can creep in. It is not hypothetical. In 2018 the dental chain Kool Smiles and its manager Benevis paid $23.9 million to settle federal allegations that they billed Medicaid for medically unnecessary procedures on children, under a bonus system that rewarded production. Watchdogs argue the structure itself deserves scrutiny; the industry counters that DSOs widen access and leave clinical calls to dentists.